UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25 SEC FILE NUMBER
0-27072
NOTIFICATION OF LATE FILING ---------------
CUSIP NUMBER
42366C103
(Check One): |X|Form 10-K |_|Form 20-F |_|Form 11-K |_|Form 10-Q |_|Form N-SAR
For Period Ended: 12/31/01
-------------------
( ) Transition Report on Form 10-K
( ) Transition Report on Form 20-F
( ) Transition Report on Form 11-K
( ) Transition Report on Form 10-Q
( ) Transition Report on Form N-SAR
For the Transition Period Ended:_____________________________________
-------------------------------------------------------------------------------
Read Instructions (on back page) Before Preparing Form. Please Print or Type.
NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION
HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.
-------------------------------------------------------------------------------
If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
-------------------------------------------------------------------------------
PART I -- REGISTRANT INFORMATION
-------------------------------------------------------------------------------
Full Name of Registrants:
Hemispherx Biopharma, Inc.
-------------------------------------------------------------------------------
Former Name if Applicable
-------------------------------------------------------------------------------
Address of Principal Executive Offices (Street and Number)
1617 JFK Boulevard
-------------------------------------------------------------------------------
City, State and Zip Code
Philadelphia, PA 19103
-------------------------------------------------------------------------------
PART II - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed (Check box if appropriate)
/ / (a) The reasons described in reasonable detail in Part III
of this form could not be eliminated without
unreasonable effort or expense;
/X/ (b) The subject annual report on Form 10-KSB will be filed
on or before the fifteenth calendar day following the
prescribed due date; and
/ / (c) The accountant's statement or other exhibit required by
Rule 12(b)-25(c) has been attached if applicable.
PART III -- NARRATIVE
State below in reasonable detail the reasons why the Form 10-K could not
be filed within the prescribed time period. (Attach Extra Sheets If Needed)
The registrant was unable to file its Form 10-K for the period ended
December 31, 2001 without unreasonable expense and effort due to its inability
to finish the required financial statements within a sufficient time for
management to review the financial statements with its independent accountants
and to prepare the management discussion and analysis. This annual report will
be filed on or before the fifteenth calendar day following the prescribed due
date.
PART IV --OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to
this notification:
Robert Peterson (215) 988-0080
--------------------------------------------------------------------------
Name Area Code Telephone Number
(2)Have all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months
(or for such shorter) period that the registrant was required to file
such reports) been filed? If answer is no, identify report(s).
|X| Yes | | No
---------------------------------------------------------------------------
(3)Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the
subject report or portion thereof?
| | Yes |X| No
If so, attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
---------------------------------------------------------------------------
Hemispherx Biopharma, Inc.
-------------------------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on their behalf by the
undersigned hereunto duly authorized.
Date March 29, 2002 By /x/ Robert E. Peterson
--------------------------- ---------------------------------------
Robert E. Peterson
Chief Financial Officer
Instruction: The form may be signed by an executive officer of the registrant
or by any other duly authorized representative. The name and title of the
person signing the form shall be typed or printed beneath the
signature. If the statement is signed on behalf of the registrant
by an authorized representative (other than an executive officer),
evidence of the representative's authority to sign on behalf of the registrant
shall be filed with the form.
-----------------------------------ATTENTION-----------------------------------
INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL
VIOLATIONS (SEE 18 U.S.C. 1001).
-------------------------------------------------------------------------------